Core Insights - Solventum (SOLV) reported $2.16 billion in revenue for Q2 2025, a year-over-year increase of 3.8% and an EPS of $1.69 compared to $1.56 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] - The company’s stock has returned -2.2% over the past month, underperforming the Zacks S&P 500 composite's +1.2% change, and currently holds a Zacks Rank 4 (Sell) [3] Financial Performance Metrics - Net Sales in MedSurg reached $1.22 billion, surpassing the $1.18 billion average estimate, reflecting a +4.8% year-over-year change [4] - Net Sales in Purification and Filtration were $252 million, exceeding the estimated $242.52 million, with a +5.9% year-over-year change [4] - Net Sales in Health Information Systems totaled $339 million, slightly above the $334.42 million estimate, marking a +3.4% year-over-year change [4] - Net Sales in Dental Solutions amounted to $338 million, compared to the estimated $332.9 million, representing a +2.1% year-over-year change [4] - Operating Income in MedSurg was $210 million, below the estimated $215.41 million [4] - Operating Income in Purification and Filtration was $48 million, significantly above the estimated $20.15 million [4] - Operating Income in Health Information Systems reached $120 million, exceeding the estimated $112.01 million [4] - Operating Income in Dental Solutions was $96 million, above the estimated $89.41 million [4]

Core Insights - Solventum (SOLV) is expected to report quarterly earnings of $1.45 per share, a decline of 7.1% year-over-year, with revenues projected at $2.12 billion, reflecting a 1.9% increase compared to the previous year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating analysts have reassessed their initial estimates [1][2] - The stock has returned -4% over the past month, underperforming the Zacks S&P 500 composite, which increased by 1% [5] Revenue Estimates - Analysts forecast 'Net Sales- MedSurg' to reach $1.18 billion, indicating a year-over-year change of +1.6% [3] - 'Net Sales- Purification and Filtration' is predicted to be $242.52 million, reflecting a year-over-year increase of +1.9% [4] - The consensus estimate for 'Net Sales- Health Information Systems' stands at $334.42 million, suggesting a +2% change from the year-ago quarter [4] - 'Net Sales- Dental Solutions' is expected to arrive at $332.90 million, indicating a +0.6% year-over-year change [4]

Core Insights - Solventum (SOLV) reported revenue of $2.07 billion for the quarter ended March 2025, reflecting a year-over-year increase of 2.7% [1] - The company's EPS was $1.34, down from $2.08 in the same quarter last year, but exceeded the consensus estimate of $1.19, resulting in an EPS surprise of +12.61% [1] - The reported revenue surpassed the Zacks Consensus Estimate of $2 billion, yielding a revenue surprise of +3.37% [1] Financial Performance Metrics - Net Sales in MedSurg reached $1.16 billion, exceeding the average estimate of $1.10 billion from three analysts [4] - Net Sales in Purification and Filtration were $242 million, slightly below the average estimate of $242.25 million [4] - Net Sales in Health Information Systems totaled $329 million, surpassing the average estimate of $319.96 million [4] - Net Sales in Dental Solutions amounted to $328 million, exceeding the average estimate of $325.61 million [4] - Operating Income in MedSurg was $206 million, below the average estimate of $229.10 million [4] - Operating Income in Purification and Filtration was $35 million, above the average estimate of $31.92 million [4] - Operating Income in Health Information Systems reached $109 million, exceeding the average estimate of $104.45 million [4] - Operating Income in Dental Solutions was $78 million, below the average estimate of $95.98 million [4] Stock Performance - Solventum's shares have returned -4.5% over the past month, contrasting with the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]